相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Structure-based optimisation of orally active & reversible MetAP-2 inhibitors maintaining a tight 'molecular budget'
David J. Hirst et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
MetAP2 inhibition increases energy expenditure through direct action on brown adipocytes
Huey-Jing Huang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Discovery and Structure-Based Optimization of Next-Generation Reversible Methionine Aminopeptidase-2 (MetAP-2) Inhibitors
Timo Heinrich et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors
Pamela J. Farrell et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Identification of Methionine Aminopeptidase-2 (MetAP-2) Inhibitor M8891: A Clinical Compound for the Treatment of Cancer
Timo Heinrich et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
N-degron and C-degron pathways of protein degradation
Alexander Varshavsky
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Suppression of glioblastoma growth and angiogenesis through molecular targeting of methionine aminopeptidase-2
Ming Lin et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Single and multiple dose evaluation of a novel MetAP2 inhibitor: Results of a randomized, double-blind, placebo-controlled clinical trial
Jaret Malloy et al.
DIABETES OBESITY & METABOLISM (2018)
Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial
Joseph Proietto et al.
DIABETOLOGIA (2018)
Preclinical Efficacy and Safety of the Novel Antidiabetic, Antiobesity MetAP2 Inhibitor ZGN-1061
Bryan F. Burkey et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)
Structural and genomic decoding of human and plant myristoylomes reveals a definitive recognition pattern
Benoit Castrec et al.
NATURE CHEMICAL BIOLOGY (2018)
Interrelationship of canonical and non-canonical Wnt signalling pathways in chronic metabolic diseases
Ian Ackers et al.
DIABETES & VASCULAR DISEASE RESEARCH (2018)
A Daple-Akt feed-forward loop enhances noncanonical Wnt signals by compartmentalizing β-catenin
Nicolas Aznar et al.
MOLECULAR BIOLOGY OF THE CELL (2017)
Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial
Shawn E. McCandless et al.
DIABETES OBESITY & METABOLISM (2017)
Novel reversible methionine aminopeptidase-2 (MetAP-2) inhibitors based on purine and related bicyclic templates
Timo Heinrich et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Spiroepoxytriazoles Are Fumagillin-like Irreversible Inhibitors of MetAP2 with Potent Cellular Activity
Michael Morgen et al.
ACS CHEMICAL BIOLOGY (2016)
Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 2
Christopher McBride et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 1
Zacharia Cheruvallath et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
N-terminal protein modifications: Bringing back into play the ribosome
Carmela Giglione et al.
BIOCHIMIE (2015)
Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity
Amit Joharapurkar et al.
Diabetes Metabolic Syndrome and Obesity-Targets and Therapy (2014)
Ascending Dose-Controlled Trial of Beloranib, a Novel Obesity Treatment for Safety, Tolerability, and Weight Loss in Obese Women
T. E. Hughes et al.
OBESITY (2013)
Orally Active Fumagillin Analogues: Transformations of a Reactive Warhead in the Gastric Environment
Christopher C. Arico-Muendel et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
The Development of MetAP-2 Inhibitors in Cancer Treatment
S. -Q. Yin et al.
CURRENT MEDICINAL CHEMISTRY (2012)
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy
Sang Joon Shin et al.
INVESTIGATIONAL NEW DRUGS (2012)
Contributions of Angiogenesis to Inflammation, Joint Damage, and Pain in a Rat Model of Osteoarthritis
Sadaf Ashraf et al.
ARTHRITIS AND RHEUMATISM (2011)
Methionine aminopeptidase 2 is required for HSC initiation and proliferation
Alvin C. H. Ma et al.
BLOOD (2011)
Disruption of Wnt Planar Cell Polarity Signaling by Aberrant Accumulation of the MetAP-2 Substrate Rab37
Thomas B. Sundberg et al.
CHEMISTRY & BIOLOGY (2011)
Protein N-Terminal Processing: Substrate Specificity of Escherichia coli and Human Methionine Aminopeptidases
Qing Xiao et al.
BIOCHEMISTRY (2010)
A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer
Sang Joon Shin et al.
INVESTIGATIONAL NEW DRUGS (2010)
Fumagillin Reduces Adipose Tissue Formation in Murine Models of Nutritionally Induced Obesity
Henri R. Lijnen et al.
OBESITY (2010)
Immunomodulatory activity of a methionine aminopeptidase-2 inhibitor on B cell differentiation
R. C. Priest et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
The ribosome as a platform for co-translational processing, folding and targeting of newly synthesized proteins
Guenter Kramer et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2009)
An orally delivered small-molecule formulation with antiangiogenic and anticancer activity
Ofra Benny et al.
NATURE BIOTECHNOLOGY (2008)
Ectopic expression of methionine aminopeptidase-2 causes cell transformation and stimulates proliferation
L. A. Tucker et al.
ONCOGENE (2008)
Correlation of tumor growth suppression and methionine aminopetidase-2 activity blockade using an orally active inhibitor
Jieyi Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
FGFR1/PI3K/AKT signaling pathway is a novel target for Antiangiogenic effects of the cancer drug fumagillin (TNP-470)
Gregory J. Chen et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
Highly potent inhibitors of methionine aminopeptidase-2 based on a 1,2,4-triazole pharmacophore
Joseph P. Marino et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Autoproteolysis of rat p67 generates several peptide fragments:: The N-terminal fragment, p26, is required for the protection of eIF2α from phosphorylation
Bansidhar Datta et al.
BIOCHEMISTRY (2007)
Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732
Yoo Mee Kim et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2007)
A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer
Herlinde Dumez et al.
ANTI-CANCER DRUGS (2007)
The proteomics of N-terminal methionine cleavage
Frederic Frottin et al.
MOLECULAR & CELLULAR PROTEOMICS (2006)
A chemical and genetic approach to the mode of action of fumagillin
Yi Zhang et al.
CHEMISTRY & BIOLOGY (2006)
Targeted gene disruption of methionine aminopeptidase 2 results in an embryonic gastrulation defect and endothelial cell growth arrest
Jing-Ruey J. Yeh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties
M Kawai et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Discovery and optimization of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2: A structural basis for the reduction of albumin binding
George S. Sheppard et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
A human protein atlas for normal and cancer tissues based on antibody proteomics
M Uhlén et al.
MOLECULAR & CELLULAR PROTEOMICS (2005)
Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models
MJ Morowitz et al.
CLINICAL CANCER RESEARCH (2005)
General pharmacology of CKD-732, a new anticancer agent: Effects on central nervous, cardiovascular, and respiratory system
EJ Kim et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2005)
Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470
R Satchi-Fainaro et al.
NATURE MEDICINE (2004)
3-Amino-2-hydroxyamides and related compounds as inhibitors of methionine aminopeptidase-2
GS Sheppard et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Rho activity critically and selectively regulates endothelial cell organization during angiogenesis
MV Hoang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis
SG Bernier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice
E Bråkenhielm et al.
CIRCULATION RESEARCH (2004)
Protein N-terminal methionine excision
C Giglione et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2004)
Proteomics-based target identification - Bengamides as a new class of methionine aminopeptidase inhibitors
H Towbin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
High expression of methionine aminopeptidase type 2 in germinal center B cells and their neoplastic counterparts
T Kanno et al.
LABORATORY INVESTIGATION (2002)
The specificity in vivo of two distinct methionine aminopeptidases in Saccharomyces cerevisiae
SP Chen et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2002)
Protection of translation initiation factor eIF2 phosphorylation correlates with eIF2-associated glycoprotein p67 levels and requires the lysine-rich domain I of p67
R Datta et al.
BIOCHIMIE (2001)
Methionine aminopeptidase-2 regulates human mesothelioma cell survival - Role of bcl-2 expression and telomerase activity
A Catalano et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
KM Sakamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1
Y Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
TNP-470: an angiogenesis inhibitor in clinical development for cancer
EA Kruger et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2000)
分享论文
